Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours

Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours

18 May 2017

Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.

The promising results from a clinical trial developed and run by investigators at Melanoma Institute Australia are being presented in Chicago at the world’s largest oncology conference, the American Society of Clinical Oncology (ASCO) Annual Meeting, attended by more than 30,000 delegates from around the world. 

The ground-breaking Anti-PD1 Brain Collaboration (ABC) clinical trial involved advanced melanoma patients being given a combination of two different immunotherapy drugs: nivolumab (Opdivo®) and ipilimumab (Yervoy®).

Results from an early analysis of this trial show 79% of advanced melanoma patients with brain metastases treated with the combination immunotherapy were still alive at six months. 66% of those who got nivolumab alone were also alive after six months.

Typically, patients with active brain metastases survive only four to five months and never even used to be admitted to clinical trials because their prognosis was so dire.

“This is an absolute game-changer for how we treat patients with advanced melanoma which has spread to the brain. It provides new hope to the 1,800 Australians expected to die from melanoma this year,” said Professor Georgina Long, the study’s chief investigator, Conjoint Medical Director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research at The University of Sydney.

“Quite simply, having brain metastases is no longer a death sentence,” she said. “We can now offer additional years of life and also the hope of ultimately beating this disease to a significant number of people.”

In February 2016, Australia approved the use of nivolumab for advanced melanoma patients as a stand-alone treatment or in combination with ipilimumab.

However, patients with brain metastases were excluded from previous clinical trials, including the ones that led to the drugs’ approval. This was what prompted Melanoma Institute Australia to develop and run the world-first ABC trial.

“I have melanoma patients with brain metastases who would not be alive today if they had not participated in this trial,” Professor Long said.

The study also examined patients who had no previous drug therapy prior to joining the trial, and those who received previous targeted drug therapy which is effective in patients with BRAF mutations in their melanoma.

It found that the combination of nivolumab and ipilimumab was more active in patients who had not received prior targeted BRAF-directed drug therapy.

Under the current Pharmaceutical Benefits Scheme (PBS) in Australia, doctors are restricted in the order in which they can prescribe the targeted BRAF-directed drug therapies and immunotherapy as treatments for melanoma. The restrictions make it very difficult to give immunotherapy first to patients who have the BRAF mutation in their melanoma (approximately 40% of all melanoma patients).

However, this new research strongly suggests that immunotherapy should be the first-line treatment in suitable patients, in particular, those with brain metastases.

Young dad, Leigh Miller (pictured here), is just one of the patients on the ABC Trial who has had a remarkable turnaround.

Australasian Melanoma Conference AMC2021
19 Nov - 20 Feb 2021

Australasian Melanoma Conference AMC2021

The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.

Predicting disease spread in thin melanoma
05 Mar 2021

Predicting disease spread in thin melanoma

A new MIA online risk calculator for clinicians can determine the likelihood of thin melanoma spreading.   

Tags: melanoma
Exploring our own clinical questions through MIA's new trials initiative
04 Mar 2021

Exploring our own clinical questions through MIA's new trials initiative

MIA has recently established a new division of our Clinical Trials Program which co-ordinates and manages investigator-led multi-centre trials. 

Tags: melanoma
Young researchers awarded Fellowships to pursue innovative treatments for melanoma
04 Mar 2021

Young researchers awarded Fellowships to pursue innovative treatments for melanoma

Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.

Tags: melanoma
Young researchers receive boost to develop innovative treatment for melanoma
04 Mar 2021

Young researchers receive boost to develop innovative treatment for melanoma

Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.

Tags: melanoma
Launch of Melanoma March 2021
01 Mar 2021

Launch of Melanoma March 2021

Aussies urged to leave their footprint on melanoma as efforts step up to save lives from the disease.

Tags: melanoma
WA Melanoma Community Forum
25 Mar 2021

WA Melanoma Community Forum

An evening for WA melanoma patients, carers and the wider melanoma community, where speakers will provide updates on melanoma research, treatment and support.  

Olivia Vivian announced as MIA ambassador
12 Feb 2021

Olivia Vivian announced as MIA ambassador

Olivia is using her Ninja star power to shine a spotlight on melanoma prevention - in memory of her dad. 

Tags: melanoma
Melanoma breakthrough - neoadjuvant treatment saving lives.
09 Feb 2021

Melanoma breakthrough - neoadjuvant treatment saving lives.

Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.

Tags: melanoma
Melanoma breakthrough - neoadjuvant therapy saving lives.
09 Feb 2021

Melanoma breakthrough - neoadjuvant therapy saving lives.

Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.

Tags: melanoma
Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
04 Feb 2021

Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?

New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.

Tags: melanoma
Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
04 Feb 2021

Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?

New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.

Tags: melanoma
A message to all Australians from melanoma patient Stuart Taylor
16 Dec 2020

A message to all Australians from melanoma patient Stuart Taylor

Stuart has advanced melanoma which is not responding to treatment. He has shared his story on ABC's 7:30 in the hope that others can escape the same fate. 

Tags: melanoma
Olivia Vivian nominates MIA as Charity Partner on Channel 9's Celebrity Apprentice.
02 Dec 2020

Olivia Vivian nominates MIA as Charity Partner on Channel 9's Celebrity Apprentice.

A Ninja Warrior legend and Olympic gymnast, Olivia knows first hand the devastating impact of melanoma.

Tags: melanoma
It's 'Game On Mole' this summer!
01 Dec 2020

It's 'Game On Mole' this summer!

All Australians are urged to join the fight against melanoma this summer. 

Tags: melanoma
Prof Richard Scolyer named Outstanding Cancer Researcher of the Year  
27 Nov 2020

Prof Richard Scolyer named Outstanding Cancer Researcher of the Year  

The ground-breaking work of MIA's Co-Medical Director Prof Richard Scolyer has been recognised with NSW’s highest accolade for cancer research. 

Tags: melanoma
Dr James Wilmott wins 2020 Wildfire Highly Cited Publication Award
24 Nov 2020

Dr James Wilmott wins 2020 Wildfire Highly Cited Publication Award

A landmark study led by MIA's Dr Willmott is making a difference to melanoma treatment around the globe.

Tags: melanoma
MIA researchers feature on prestigious Highly Cited Researchers 2020 List
18 Nov 2020

MIA researchers feature on prestigious Highly Cited Researchers 2020 List

The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.

Tags: melanoma
Game On Mole is back this summer!
13 Nov 2020

Game On Mole is back this summer!

The uniquely Aussie awareness campaign ‘Game On Mole’ is back for its second year – with a new look but same important message.

Tags: melanoma
RCPA recognition for Professor Richard Scolyer.
12 Nov 2020

RCPA recognition for Professor Richard Scolyer.

Professor Richard Scolyer receives The Royal College of Pathologists of Australasia Distinguished Fellow Award.

Tags: melanoma